Mr has made over 2 trades of the Xenetic Biosciences Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 35,442 units of XBIO stock worth $30,126 on 23 January 2018.
The largest trade he's ever made was exercising 100,000 units of Xenetic Biosciences Inc stock on 8 January 2018 worth over $369,000. On average, Mr trades about 9,674 units every 1 days since 2016. As of 23 January 2018 he still owns at least 64,558 units of Xenetic Biosciences Inc stock.
You can see the complete history of Mr Eisenberg stock trades at the bottom of the page.
Jeffrey F. Eisenberg Esq. is the CEO, Pres & Director at Xenetic Biosciences Inc.
As the CEO és Pres & Director of Xenetic Biosciences Inc, the total compensation of Mr Esq at Xenetic Biosciences Inc is $446,357. There are no executives at Xenetic Biosciences Inc getting paid more.
Mr Esq is 55, he's been the CEO és Pres & Director of Xenetic Biosciences Inc since . There are 6 older and 6 younger executives at Xenetic Biosciences Inc. The oldest executive at Xenetic Biosciences Inc is Roger Kornberg, 73, who is the Director.
Jeffrey's mailing address filed with the SEC is 945, Concord Street, Framingham, Middlesex County, Massachusetts, 01701, United States.
xenetic biosciences (nasdaq: xbio) is a clinical-stage biopharmaceutical company focused on discovery, research and development of next-generation biologic drugs and novel oncology therapeutics. xenetic's proprietary drug development platforms include polyxen™, which enables next generation biologic drugs by improving their half-life and other pharmacological properties. xenetic's lead investigational product candidates include fda orphan designated oncology therapeutic sodium cridanimod for the treatment of progesterone receptor negative endometrial cancer, and a polysialylated form of erythropoietin for the treatment of anemia in pre-dialysis patients with chronic kidney disease. xenetic is also working together with shire plc (formerly baxalta, baxter incorporated and baxter healthcare) to develop a novel series of polysialylated blood coagulation factors, including a next generation factor viii. this collaboration relies on xenetic's polyxen technology to conjugate polysialic acid
Xenetic Biosciences Inc executives and other stock owners filed with the SEC include: